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1684-1182/Copyright ª 2014, TaiwanPurpose: To preliminarily evaluate the immunogenicity and efficacy of the recombinant tuber-
culosis vaccine AEC/BC02 in which Ag85b and fusion protein ESAT6-CFP10 were combined with
bacillus Calmette-Gue´rin CpG and an aluminum salt-based adjuvant system.
Methods: Groups of BALB/c mice were immunized intramuscularly three times at 10-day inter-
vals with AEC/BC02 or the adjuvant alone and the vaccine-induced cell-mediated immune re-
sponses were evaluated. The efficacy of AEC/BC02 was evaluated in two guinea pig models,
one a model of prevention and the other a model of latent infection.
Results: The AEC/BC02 vaccine induced strong cellular immune responses characterized by a
high frequency of antigen-specific interferon-g-secreting T cells in mice at different time
points after the last vaccination. In the preventive model of guinea pig, AEC/BC02 did not pro-
tect against Mycobacterium tuberculosis as a pre-exposure vaccine. However, in a latent infec-
tion model of guinea pig, it effectively controlled the reactivation of M. tuberculosis and
lowered the bacterial load in the lung and spleen.uberculosis Vaccines, National Institutes for Food and Drug Control, Number 2, Tiantan Xili, Beijing
(M. Xu).
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tion and may function as a therapeutic vaccine.
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China ranks second in the world tuberculosis (TB) epidemic,
behind only India. The World Health Organization estimated
that the number of incident cases of TB in China in 2012 was
0.9e1.1 million, accounting for 12% of global cases.1 The
bacillus Calmette-Gue´rin (BCG) vaccine is widely used as
part of China’s immunization planning, but it does not
control the spread of TB in adults and cannot prevent latent
TB infection in individuals. Therefore, novel TB vaccines
are urgently needed in China.
At present, 16 TB vaccine candidates have entered
clinical trials, with seven in clinical Phase II.2 Several new
candidates are waiting to enter clinical testing. Of the 16
vaccine candidates, six are recombinant protein vaccines of
Mycobacterium tuberculosis (Mtb)-specific proteins and
novel adjuvants such as AS01 or AS02 developed by Glax-
oSmithKline,3 IC31 and CAF01 from the Statens Serum
Institut,4,5 and GLA-SE from the Infectious Disease Research
Institute.6 The new adjuvants effectively promote cellular
immunity induced by the vaccine, a step thought to be key
in preventing and controlling TB infection. With the
importance of adjuvants for subunit vaccines, we devel-
oped a new adjuvant system, BC02, based on BCG-derived
CpG and aluminum salt. Some studies have shown that,
due to a synergistic effect of CpG and aluminum, the
combination of CpG and aluminum can induce a stronger
Th1 and Th2 immune response.7,8 In our previous study, we
demonstrated that BC02 is safe and increased both antigen-
specific interleukin-12 (IL-12) secretion by peritoneal
macrophages and the number of antigen-specific T cells
that release interferon-g (IFN-g).9 Using the new adjuvant,
we used Ag85b antigen and ESAT-6/CFP-10 (EC) fusion
protein to construct a new TB vaccine candidate called
AEC/BC02.
The T cell-mediated immune response is a critical de-
fense against TB. Vaccine-induced antigen-specific poly-
functional T cells are thought to effectively control Mtb
infection or postpone TB onset, and expression of Th1 cy-
tokines such as IFN-g, tumor necrosis factor-a, and IL-12 is
important.10 However, the contribution of humoral immu-
nity to protection is controversial.11 Therefore, most
studies on the preclinical or clinical development of new TB
vaccines focus on cellular immune responses induced by
vaccination.5,12,13
At the preclinical stage, vaccine protection of animal
models is an important indicator. The ability of the vaccine
to mitigate organ lesions and reduce bacterial loads as well
as extend survival time in Mtb-infected animals directly
reflects its efficacy. Mice are the most widely used animal
models. Guinea pigs are used less frequently for evaluatingthe efficacy of new TB vaccines, but they could be more
appropriate and more stringent for vaccine testing than
mice because TB pathogenesis in guinea pigs is similar to
the process in humans.14 However, because of a limited
range of immunology reagents for evaluating the immune
response in guinea pigs, they might not be as suitable as
mice. Nonetheless, indicators relevant to vaccine protec-
tion such as organ lesions and bacterial loads can be veri-
fied in guinea pigs.
Therefore, in this study, we measured the frequency of
antigen-specific IFN-g secretion from T cells as a repre-
sentative of cellular immune response induced by the AEC/
BC02 vaccine in mice. We evaluated the efficacy of AEC/
BC02 in two guinea pig models, one a model of prevention
and the other a model of latent infection.
Materials and methods
Mice and guinea pigs
Specific-pathogen-free (SPF) BALB/c mice (female, 6e8
weeks) and Hartley guinea pigs (200e300 g) were obtained
from the Institute for Laboratory Animal Resources, Na-
tional Institutes for Food and Drug Control (NIFDC). Mice
were maintained under SPF conditions and guinea pigs
were held under barrier conditions in a Biosafety Level III
animal laboratory. All animals used in this study were
treated according to the standards of animal welfare and
reviewed by the Animal Care and Welfare Committee of
NIFDC.
Experimental vaccine
One dose of AEC/BC02 comprised 10 mg Ag85B þ 10 mg EC
in 0.2 mL (for mice) or 0.5 mL (for guinea pigs) adjuvant
BC02. The adjuvant BC02 per animal contained 75 mg CpG
and 0.2 mg aluminum hydroxide in phosphate-buffered
saline.
Bacterial strains
BCG vaccine Shanghai line (D2 PB302 line) was obtained
from the Chengdu Institute of Biological Products. The
challenge strain Mtb (American Type Culture Collection
35810 strain) was grown on Lo¨wensteineJensen medium at
37C for approximately 4 weeks before washing with Sau-
ton’s medium and grinding. Bacterial suspensions were
measured with a McNamara turbidimetric tube assay and
diluted to 1 mg/mL. The samples were stored at e70C in
aliquots.
Immunogenicity and efficacy of AEC/BC02 vaccine 599Cellular immune response in mice
Forty-eight mice were randomly divided into two groups.
One group was immunized intramuscularly three times at
10-day intervals with AEC/BC02; the other was injected
with the adjuvant BC02 for a control. At 1, 2, 4, and 8
weeks after the last vaccination, IFN-g enzyme-linked
immunosorbent spot (ELISPOT) was performed according
to the manufacturer’s instructions (Mabtech AB, Nacka
Strand, Sweden). In brief, spleen lymphocytes (2.5  105/
well) were stimulated with Ag85b peptide pools (15 amino
acids, overlapping 10 amino acids, 2 mg/mL each), EC
peptide pools (15 amino acids, overlapping 10 amino acids,
3.5 mg/mL each), media (negative control), or concanavalin
A (positive control) for 48 hours. Spots were quantified
using an ELISPOT reader (Cellular Technology Ltd, USA).
Media background was subtracted from the antigen-specific
response at each time point. Meanwhile, at 4 and 8 weeks
after the last vaccination, lymphoproliferation responses
were measured by cell counting kit-8 (CCK-8) assays
(Dojindo, Kumamoto, Japan). In brief, spleen lymphocytes
(2.5  105/well) were stimulated with Ag85b peptide pools
(15 amino acids, overlapping 10 amino acids, 2 mg/mL
each), EC peptide pools (15 amino acids, overlapping 10
amino acids, 3.5 mg/mL each) or media (negative control)
for 72 hours and 10 mL of CCK-8 solution was added to each
well for the final 6 hours of incubation. Results were shown
as stimulation index, the fold-increase in A450 nm/650 nm over
the negative control.
Evaluation in guinea pig preventive model
Guinea pigs were injected three times (Fig. 1A, weeks 9, 7,
and 5) with one dose of AEC/BC02 vaccine intramuscularly 2
weeks apart. Negative-control guinea pigs received three
equivalent doses of normal saline, and positive-controlFigure 1. Timeline of evaluation in two guinea pig models. (A) Pre
Ag85B and 10 mg EC in 0.5 mL BC02), animals were challenged with 1
(Mtb) and killed 6 weeks later. The normal saline group was the ne
5  103 CFU 5 weeks before challenge) was the positive control. (B
103e104 CFU Mtb, animals were treated with isoniazid (5 mg each)
vaccine or adjuvant BC02 six times and killed 1 week after the last
saline. EC skin test was used to detect infection status.guinea pigs were subcutaneously given a single dose of
5  103 colony forming units (CFU) BCG 5 weeks before
challenge. Five weeks after the last vaccination, guinea
pigs were challenged subcutaneously with 0.5 mL of Mtb
(102e103 CFU). Six weeks after infection, all guinea pigs
were killed for necropsy.
Evaluation in latent infection model
Guinea pigs were challenged subcutaneously with 0.5 mL of
Mtb (103e104 CFU). At Week 2 (Fig. 1B), animals had posi-
tive EC skin tests (Supplementary Fig. 1) and began to
receive isoniazid treatment (5 mg/animal) by oral gavage.
The animals were treated three times a week for 4 weeks.
At the 6th week after infection, guinea pigs were intra-
muscularly given the single dose of AEC/BC02 vaccine or
adjuvant BC02 six times at 10-day intervals; the negative-
control group was vaccinated with normal saline. One
week after final immunotherapy, all guinea pigs were killed
for necropsy.
Determination of gross pathological scores and
bacterial loads
After necropsy, pathological scores for the liver, spleen,
and lung were evaluated separately, as described previ-
ously9 and the sum was the gross pathological scores. Half
of the harvested spleens or lungs were ground with 3 mL
sterile normal saline. Homogenates were serially diluted
and plated on a modified LJ medium base. CFU were
determined after 4 weeks of incubation at 37C.
Statistical analysis
Data analysis was performed using GraphPad Prism 6.0
(GraphPad Software, USA). The one-way analysis of varianceventive model: 5 weeks after vaccination with AEC/BC02 (10 mg
02e103 colony forming units (CFU) Mycobacterium tuberculosis
gative-control and the bacillus Calmette-Gue´rin group (1 dose
) Latent infection model: 2 weeks after being challenged with
three times a week for 4 weeks and vaccinated with AEC/BC02
immunization. Negative-control guinea pigs were given normal
600 J.-b. Lu et al.followed by Tukey’s multiple comparison test or t test was
used for these studies. A p value < 0.05 was considered
significant.
Results
Antigen-specific IFN-g responses and lymphocyte
proliferation
Antigen-specific IFN-g ELISPOTs were analyzed after two or
three doses of AEC/BC02. At 1 week after the last vaccina-
tion, antigen-specific IFN-g responses were the same for
both doses. After 1 week, responses in the two-dose group
decreased with time; a slight increase in responses in the
three-dose group was observed until the 8th week (Fig. 2A),
suggesting a better response from three doses. Responses to
Ag85bwere stronger than responses to EC at each time point,
indicating that Ag85b was more strongly immunogenic. We
also performed lymphocyte proliferation assays to study
antigen-specific responses in the three-dose vaccine group.
At 4 and 8 weeks after the last vaccination, stimulation
in vitro with either Ag85b or EC significantly enhanced
lymphocyte proliferation in the three-dose vaccine group
compared with the control group (Fig. 2B). Taken together,
these data supported that AEC/BC02 vaccination induced
long-term specific cellular immune responses in mice.Figure 2. Antigen-specific T-cell responses after AEC/BC02 vacc
immunosorbent spot responses to Ag85b peptide pool and EC pep
vaccinated with two or three doses of AEC/BC02. Data are mean 
responses in BC02-vaccinated and AEC/BC02-vaccinated mice (3 do
peptide pool and EC peptide pool. The p values for BC02 and AEC/
with two-tailed t test. Data are mean  SD (n Z 6/group).Evaluation in preventive model
Comparative evaluation of AEC/BC02 and current BCG, a
test that would be conducted if AEC/BC02 was used as a
preventive vaccine, was performed. As shown in Fig. 2,
gross pathological scores for the liver, spleen, and lung in
an AEC/BC02-vaccinated group were 35.8  27.3, signifi-
cantly lower than in a normal saline control group
(62.5  11.3, p Z 0.0441) and significantly higher than a
BCG-vaccinated group (5.0  5.5, pZ 0.0196). A significant
difference between the BCG-vaccinated and normal saline
groups was also observed (p Z 0.0001). Bacterial loads in
the spleen had a similar tendency. The AEC/BC02-
vaccinated group had slightly lower bacterial counts
(5.31  0.91 log10 CFU) than the normal saline group
(5.74  0.47 log10 CFU), but the difference was not signif-
icant. No bacteria were detected in BCG-vaccinated guinea
pigs. These results indicated that BCG provided strong
protection against TB and AEC/BC02 had lower efficacy
than BCG in this model.
Evaluation in latent infection model
Mtb-infected guinea pigs were treated with antibiotics to
induce latent infection. After 4 weeks of treatment, bac-
terial loads were too low to be detected (Supplementaryination with 10-day intervals. (A) Interferon-g enzyme-linked
tide pool [for spot-forming cells (SFCs)/2  105 cells] in mice
standard deviation (SD; nZ 6/group). (B) Lymphoproliferative
ses) as stimulation index of lymphocytes in response to Ag85b
BC02 vaccination responses at each time point were evaluated
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BC02 or adjuvant BC02. In two independent experiments
(Fig. 3), after AEC/BC02 immunotherapy, guinea pigs had
lower gross pathological scores and fewer bacilli in both the
spleen (1.78 log10 CFU and 2.04 log10 CFU reduction) and
lung (1.70 log10 CFU and 2.29 log10 CFU reduction)
compared with the normal saline group. Similar but lower
reductions were observed in gross pathological scores and
bacterial loads in the adjuvant BC02-treated group. Dif-
ferences in bacterial loads between the normal saline and
AEC/BC02-treated groups were significant in the first
experiment (n Z 10/group) but not in the second (n Z 8/
group), possibly because of a decrease in the number of
animals and sampling error.Discussion
In this study, we evaluated antigen-specific cell-mediated
immunity in mice using IFN-g ELISPOT assays and lympho-
cyte proliferation tests. Long-term cellular immune re-
sponses were induced in mice receiving either two or three
vaccinations of AEC/BC02. The cellular responses were
characterized by antigen-specific IFN-g, and it was
observed that three doses gave a better response than two.
Other Th1 cytokine responses and the polyfunctional T-cell
frequency induced by AEC/BC02 remain to be determined.
At present, BCG, the only available TB vaccine, does not
protect against adult pulmonary TB. Although 10-week-old
infants who receive the BCG vaccination induce
mycobacterium-specific T-cell expression of Th1 cytokines
such as IFN-g and IL-2, protection by the BCG vaccine might
decrease with time and not recover, even if vaccination is
repeated.11,12 Therefore, new recombinant BCG and
attenuated or modified Mtb vaccine candidates have been
developed and are expected to provide higher efficacy than
BCG by enhancing antigen immunogenicity.13 Thus, all new
vaccine candidates should be compared with BCG as the
gold standard. Much evidence indicates that BCG confers
superior protective immunity against TB in mice, guinea
pig, and monkey models.5,15,16 For example, BCG maintainsFigure 3. Efficacy of AEC/BC02 compared with bacillus Calmette
way analysis of variance followed by Tukey’s multiple comparison
forming units; ND Z no bacteria detected; NS Z normal saline. A:protection for up to 50e70 weeks in guinea pigs.17 How-
ever, the new candidate vaccine AEC/BC02 did not have
similar performance in a preventive model and did not
effectively decrease either organ lesions or bacterial load
in the spleen compared with BCG (Fig. 4). Thus, AEC/BC02
was not appropriate as a preventive, pre-exposure vaccine.
The reason is probably that for the recombinant protein
vaccine only containing several antigens it is difficult to
induce sufficient protective immunity equal to that of BCG,
a live bacterial vaccine containing a variety of antigens. In
fact, in the clinical stage many recombinant protein vac-
cines against TB are not to be considered for pre-exposure
prophylaxis but for other immunization strategies, such as
booster after the BCG prime and immunotherapy of latent
infection.2
An estimated one-third of the world’s population, or
approximately 2.2 billion people, have a latent Mtb infec-
tion and 10% of these will develop active disease.18,19 The
large population with latent infections means that vaccines
will be an important preventive measure for controlling the
spread of TB. Many new vaccines have been used for
immunotherapy for latent infection. Evaluation of these
vaccines is performed in latent-infection models, often
established by infecting animals with low-dose Mtb or using
Mtb-infected animals after anti-TB drug treatment. Mouse
models have been the most frequently and earliest studied,
with few applications of guinea pig models. Treatment of
Mtb-infected guinea pigs with traditional drugs such as
isoniazid and rifampin results in a rapid drop in the number
of viable bacteria in the lung to nondetectable levels.20,21
In our study, guinea pigs challenged with Mtb subcutane-
ously had positive EC skin tests after 12e14 days
(Supplementary Fig. 1). At 4 weeks after treatment with
isoniazid, EC skin tests were positive, but no bacteria were
detected in the lung (Supplementary Fig. 2) and TB
relapsed over time. This indicated that during the drug
treatment period, a small number of Mtb were not killed
and might remain latent. Therefore, after drug withdrawal,
we vaccinated guinea pigs with AEC/BC02 to inhibit or
delay Mtb recovery. Two independent experiments admin-
istering AEC/BC02 six times showed that Mtb in guinea pigs-Gue´rin (BCG) in the preventive model (nZ 6/group). (A) One-
s test. Data are means  standard deviation. CFU Z colony
Gross pathological scores; B: Bacterial loads in spleen.
Figure 4. Evaluation of AEC/BC02 in a latent infection model. Gross pathological scores of the liver, spleen, and lung and bacterial
loads in the lung and spleen were measured in two independent experiments [nZ 10 (A) or 8 (B)/group, respectively]. Analysis was
one-way analysis of variance followed by Tukey’smultiple comparisons test for comparison among groups. Data aremeans standard
deviation. CFUZ colony forming units; NSZ normal saline. A: Gross pathological scores; B: Bacterial loads in spleen.
602 J.-b. Lu et al.was effectively controlled with fewer visible bacteria in the
lung and spleen, and milder lesions on organs. By contrast,
a saline-treated group showed increased numbers of bac-
teria and severe lesions on the organs. Guinea pigs treated
with adjuvant BC02 also had fewer severe organ lesions and
lower bacterial loads than guinea pigs treated with saline.
This result might be because BCG-derived CpG is a
component of BC02 and had a therapeutic effect on Mtb
infection.22,23
It needs to be pointed out that the challenge route we
performed in this study was a subcutaneous model.
Although most researchers preferred the aerosol infection
model, which was consistent with Mtb infection in human
and more appropriate, our previous study suggested thatprotection of vaccines in guinea pigs could be judged
indifferently in these two different challenge models24 and
subcutaneous route may be more convenient for chal-
lenging large quantities of animals. Nevertheless, in our
future study, the challenge model will still require optimi-
zation to copy the natural infection.
In conclusion, we developed a subunit vaccine AEC/
BC02, comprising Ag85b and EC with a new adjuvant system
based on BCG-derived CpG and aluminum salt. This
vaccine-induced long-term cellular immune response in
mice, but is not suitable as a preventive vaccine for guinea
pigs. However, it protected guinea pigs against progressive
disease in a model of infection and might be used as a
therapeutic vaccine.
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